‘Undercover chlamydia’: Inquiries confirm no naughty deeds under the covers

+Practice

In print

SEXUAL HEALTH

‘Undercover chlamydia’: Inquiries confirm no naughty deeds under the covers

2 February 2022

By Massimo Giola

Wednesday 2 February 2022, 12:20 AM

No need to go undercover to expose an extramarital affair, many chlamydia “reinfections” are due to endogenous recolonisation [Image: Devin Kaselnak on Unsplash]

We welcome back infectious disease and sexual health specialist Massimo Giola as a regular contributor in 2022. Starting with chlamydia, each article in this series will cover one topic of interest, present a clinical case and explain the rationale for some of the recommendations in the new Aotearoa New Zealand STI Management Guidelines for use in primary care

Key points, There is growing evidence that sexually transmitted Chlamydia trachomatis establishes a persistent rectal reservoir that is refractory to treatment wi, Pract Green w Pale Yellow

Reproductive Health

Genitourinary

Infectious Disease

Medicines and Therapies

References

Further reading:

Khosropour CM, Dombrowski JC, Vojtech L, et al. Rectal Chlamydia trachomatis infection: A narrative review of the state of the science and research priorities. Sex Transm Dis 2021;48(12):e223–27.
Rank RG, Yeruva L. Hidden in plain sight: chlamydial gastrointestinal infection and its relevance to persistence in human genital infection. Infect Immun 2014;82(4):1362–71.
Kong FY, Tabrizi SN, Fairley CK, et al. The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis. J Antimicrob Chemother 2015;70(5):1290–97.
Chandra NL, Broad C, Folkard K, et al. Detection of Chlamydia trachomatis in rectal specimens in women and its association with anal intercourse: a systematic review and meta-analysis. Sex Transm Infect 2018;94(5):320–26.

How to Treat

+How to treat

Heart failure

Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality

Wednesday 29 January 2025, 12:45 AM